# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Equillium released topline data from its Phase 2 study of EQ101 in adult patients with alopecia areata, a disease that results ...
20% of all subjects that completed the 24-week treatment period achieved SALT ≤ 2029% of completed subjects with moderate to se...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $5 price target.